The Migraine and Pain Study GeneBank at Scripps Clinic Registry (MAPS)

NCT01004835 | Completed

• 1 other identifier: HSC# 08-5099
• Study Type: observational
• Target: 61
• Locations: 1 country
• Sites: 1

Brief Summary

The objective of this study is to obtain blood or saliva samples to define genes for migraine and pain diseases.

Conditions

Migraine Disease

Keywords

migraine

Outcome Measures

Primary Outcomes (1)

• Gene identification

  By creating a MAPS GeneBank from these patients' blood/saliva donations we will ultimately be able to define genes for migraine and pain diseases.

  end of study

Study Arms (1)

Migraine Disease

Patients 10 to 18 years of age with the diagnosis of Migraine disease and at least one of their biologic parents will be included in this study.

Eligibility Criteria

• Age: 10 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Subjects will be recruited from the Migraine disease patient population at Scripps Clinic and around Southern California.

You may qualify if:

• Family members (genetic duo or trio), consisting of an adolescent 10 to 18 years of age and at least one of their biologic parents willing to be participate in trial
• Adolescent and at least 1 biologic parent with Migraine diagnosis confirmed by Dr. Christy Jackson
• Is reliable, cooperative and willing to comply with all protocol-specified procedures and/or sub-study if consented
• Able to understand and grant informed consent

You may not qualify if:

• Patient has been previously enrolled in the MAP GeneBank at Scripps Clinic Registry
• Has a significant chronic medical condition (i.e.chronic meningitis or a secondary origin/cause of headache) which, in the investigator's option, may interfere with the patient's optimal participation in the study
• Treatment with any investigational agents or devices within 30 days preceding enrollment in the study
• Has undergone ECT within 90 days preceding enrollment in the study

Sponsors & Collaborators

• Scripps Translational Science Institute: lead

Study Sites (1)

Scrippshealth

La Jolla, California, 92037, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

Approximately 20 milliliters of blood will be dispensed as follows: 2 X 8.5 ml PAX DNA Tubes OR 2 mLs of Saliva may be collected from each patient in a provided container. Saliva will only be collected on those individuals who do not wish to undergo phlebotomy for blood collection.

MeSH Terms

Conditions

Migraine Disorders

Condition Hierarchy (Ancestors)

Headache Disorders, Primary; Headache Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases

Study Officials

• Christy M Jackson, M.D.

  Scrippshealth

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: FAMILY BASED
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director, Scripps Translational Science Institute

Study Record Dates

• First Submitted: October 29, 2009
• First Posted: October 30, 2009
• Study Start: January 1, 2009
• Primary Completion: May 1, 2015
• Study Completion: May 1, 2015
• Last Updated: October 16, 2015

Record last verified: 2015-10

Locations

US (1)